Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: Antigens for multi-targeted antibody-guided therapy

Journal of Histochemistry and Cytochemistry

Volumn 55, Issue 8, 2007, Pages 867-875

  Chauhan, Subhash C ^a,b   Vinayek, Namita ^a   Maher, Diane M ^a   Bell, Maria C ^b   Dunham, Katrina A ^a   Koch, Michael D ^b   Lio, Yuhlong ^a   Jaggi, Meena ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

CA125; MUC1; Ovarian cancer; Ovarian cancer therapy; TAG 72

Indexed keywords

CA 125 ANTIGEN; MUCIN 1; TAG 72 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ANTIBODIES; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; DRUG CARRIERS; FEMALE; GLYCOPROTEINS; HUMANS; MUCINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447530932     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.7A7213.2007     Document Type: Article

References (44)

1. Alexander-Sefre F, Menon U, Jacobs IJ (2002) Ovarian cancer screening. Hosp Med 63:210-213
2. 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8:2806-2811
3. 177Lu-CC49: a phase I/II study. Gynecol Oncol 65:94-101
4. Armstrong DK (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(suppl 5):20-28
5. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC (1998) The biology of ovarian cancer. Semin Oncol 25:281-304
6. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22:255-288
7. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, et al. (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(suppl 3):274-281
8. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D (2002) Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13:603-608
9. 90Y- labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res 59:2635-2643
10. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, et al. (1997) Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 38:858-870
11. Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, Moniaux N, et al. (2006) Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol 19:1386-1394
12. Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, Buraggi GL, et al. (1995) Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A:686-690
13. DeNardo GL, O'Donnell RT, DeNardo SJ (2001) Radiolabeled antilymphoma antibodies. Cancer Chemother Biol Response Modif 19:297-308
14. DeNardo SJ, Kroger LA, DeNardo GL (1999) A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 11:563-569
15. Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert HE, McKenzie CG, Soutter P, et al. (1987) Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5:1890-1899
16. Giuntoli RL 2nd, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA (1998) Mucin gene expression in ovarian cancers. Cancer Res 58:5546-5550
17. Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713
18. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4:45-60
19. Hong K, Kirpotin DB, Park JW, Shao Y, Shalaby R, Colbern G, Benz CC, et al. (1999) Anti-HER2 immunoliposomes for targeted drug delivery. Ann NY Acad Sci 886:293-296
20. Janssen ML, Pels W, Massuger LF, Oyen WJ, Boonstra H, Corstens FH, Boerman OC (2003) Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. Int J Gynecol Cancer 13:607-613
21. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106-130
22. Kang BK, Chon SK, Kim SH, Jeong SY, Kim MS, Cho SH, Lee HB, et al. (2004) Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int J Pharm 286:147-156
23. Mahe MA, Fumoleau P, Fabbro M, Guastalla JP, Faurous P, Chauvot P, Chetanoud L, et al. (1999) A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 5:3249-3253s
24. Menon U, Jacobs I (2002) Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16:469-482
25. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM Jr, et al. (2001) Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 16:305-315
26. Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD, Wheeler RH, et al. (1996) Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 37:1491-1496
27. Milenic DE, Brady ED, Brechbiel MW (2004a) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488-499
28. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW (2004b) Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 10:7834-7841
29. 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 20:557-568
30. Ozols RF (2002a) Future directions in the treatment of ovarian cancer. Semin Oncol 29:32-42
31. Ozols RF (2002b) Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 20:1161-1163
32. Ozols RF (2002c) Update on the management of ovarian cancer. Cancer J 8(suppl 1):S22-30
33. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, et al. (1995) Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 92:1327-1331
34. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC (1997a) Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 118:153-160
35. Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC (1997b) Immunoliposomes for cancer treatment. Adv Pharmacol 40:399-435
36. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, et al. (2001) Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95-113
37. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, et al. (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267-277
38. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2:373-383
39. Sahoo SK, Ma W, Labhasetwar V (2004) Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112:335-340
40. Schneider-Gadicke E, Humm JL, Lau CC, Macklis RM, Bastert G, Knapp RC (1992) Analysis of cytotoxicity of 131I-labelled OC125 F(ab′)2 on human epithelial ovarian cancer cell lines. Radiother Oncol 23:150-159
41. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, Siegel JA, et al. (1993) Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 71:2082-2096
42. Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J (1986) Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 76:995-1006
43. Thor A, Muraro R, Gorstein F, Ohuchi N, Viglione M, Szpak CA, Johnston WW, et al. (1987) Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity. Cancer Res 47:505-512
44. Vasir JK, Labhasetwar V (2005) Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 4:363-374